Analysis of polypharmacy in schizophrenia patients in Ponta Grossa
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2024.205322Keywords:
Schizophrenia, Antipsychotics, Clozapine, PolypharmacyAbstract
Introduction: Schizophrenia is a chronic disorder requiring significant healthcare resources, and its treatment is primarily based on antipsychotics, ideally prescribed as monotherapy. Polypharmacy is generally discouraged due to the increased risk of side effects without clear clinical benefits. Objectives: This study aims to determine the prevalence of antipsychotic polypharmacy, occurrences of high doses and underdoses of antipsychotics, and the use of clozapine at CAPS II in Ponta Grossa, PR. Methodology: A total of 483 medical records were analyzed, with 340 records excluded from the study. The prescriptions of 143 patients diagnosed with schizophrenia were reviewed for the period from 01/01/2021 to 26/09/2022 at CAPS II in Ponta Grossa, PR. Antipsychotic polypharmacy was
defined as the prescription of two or more antipsychotic medications. High-dose was defined as any prescription with a dose exceeding the maximum recommended dose or a cumulative dose exceeding 100% of the maximum doses for each drug. Underdose was defined as any prescription below the recommended dose in the literature. Results: Among the patients with schizophrenia, 59.44% were undergoing polypharmacy treatment, 21.67% were prescribed high doses of antipsychotics, and 29.37% were receiving underdoses. Conclusion: The therapeutic profile of patients at CAPS II diverges from the existing literature. The rate of polypharmacy and high-dose prescriptions is higher compared to other studies, while the use of clozapine is considerably lower.
Downloads
References
American Psychiatric Association (APA). Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5. ed. Porto Alegre: Artmed, 2014.
Baandrup L. Polypharmacy in schizophrenia. Basic & Clinical Pharmacology & Toxicology [Internet]. 2020 Jan 15 [cited 2022 Dec 1];126(3):183–92. Available from: https://pubmed.ncbi.nlm.nih.gov/31908124/
GBD Results [Internet]. Institute for Health Metrics and Evaluation. 2022 [cited 2022 Dec 1]. Available from: https://vizhub.healthdata.org/gbd-results/?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7
Carteri RB, Oses JP, Cardoso T de A, Moreira FP, Jansen K, Silva RA da. A closer look at the epidemiology of schizophrenia and common mental disorders in Brazil. Dementia & Neuropsychologia [Internet]. 2020 Sep [cited 2022 Dec 1];14(3):283–9. Available from: https://www.scielo.br/j/dn/a/6NjRRrzDWPk6PjQv3kMKGTK/?lang=en
Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin [Internet]. 2018 May 12 [cited 2022 Dec 1];44(6):1195–203. Available from: https://pubmed.ncbi.nlm.nih.gov/29762765/
Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet Psychiatry [Internet]. 2017 Apr [cited 2022 Dec 1];4(4):295–301. Available from: https://pubmed.ncbi.nlm.nih.gov/28237639/
Laursen TM, Nordentoft M, Mortensen PB. Excess Early Mortality in Schizophrenia. Annual Review of Clinical Psychology [Internet]. 2014 Mar 28 [cited 2022 Dec 1];10(1):425–48. Available from: https://pubmed.ncbi.nlm.nih.gov/24313570/
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. The Canadian Journal of Psychiatry [Internet]. 2017 Jul 13 [cited 2022 Dec 1];62(9):604–16. Available from: https://pubmed.ncbi.nlm.nih.gov/28703015/
National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management [Internet]. [London]: NICE; 2014 [updated 2014 Mar; cited 2022 Dec 16]. (Clinical guideline [CG178]). Available from: https://www.nice.org.uk/guidance/cg178
Taylor D, E. BTR, Young A. The Maudsley prescribing guidelines in psychiatry. 14th ed. Hoboken, NJ, NJ: Wiley Blackwell; 2021.
Castle DJ, Buckley PF. Schizophrenia. 2nd ed. London, England: Oxford University Press; 2014.
Lin S-K. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? International Journal of Neuropsychopharmacology [Internet]. 2019 Dec 23 [cited 2022 Dec 17];23(2):125–31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093996/
Stahl SM. Stahl’s Essential Psychopharmacology : neuroscientific basis and practical applications. 5th ed. Editorial: S.L.: Cambridge Univ Press; 2021.
Patrick V, Levin E, Schleifer S. Antipsychotic Polypharmacy: Is There Evidence for its Use? Journal of Psychiatric Practice [Internet]. 2005 Jul [cited 2023 Mar 7];11(4):248–57. Available from: https://pubmed.ncbi.nlm.nih.gov/16041235/
Christy J, Burnside D, Agius M. Combining antipsychotics; is this strategy useful? Psychiatria Danubina [Internet]. 2014 [cited 2023 Mar 7];26 Suppl 1. Available from: https://pubmed.ncbi.nlm.nih.gov/25413558/
Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Drugs [Internet]. 2021 Jul [cited 2023 Mar 7];81(11):1273–84. Available from: https://link.springer.com/article/10.1007/s40265-021-01556-4
Grech P, Taylor D. Long-term antipsychotic polypharmacy: how does it start, why does it continue? Therapeutic Advances in Psychopharmacology [Internet]. 2011 Nov 30 [cited 2022 Dec 1];2(1):5–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736927/
Armstrong KS, Temmingh H. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country. Revista Brasileira de Psiquiatria [Internet]. 2017 Feb 6 [cited 2022 Dec 1];39(4):293–301. Available from: https://www.scielo.br/j/rbp/a/qMrLPqJdkPDfFrDyCrQmC5w/?lang=en
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry [Internet]. 2017 Mar [cited 2022 Dec 1];174(3):216–29. Available from: https://pubmed.ncbi.nlm.nih.gov/27919182/
Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. British Medical Bulletin [Internet]. 2020 Sep [cited 2022 Dec 1];135(1):73–89. Available from: https://pubmed.ncbi.nlm.nih.gov/32885238/
Potkin SG, Kane JM, Correll CU, Lindenmayer J-P, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophrenia [Internet]. 2020 Jan 7 [cited 2022 Dec 1];6(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31911624/
Lal S, Nair NPV. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatrica Scandinavica [Internet]. 1992 Mar [cited 2022 Dec 18];85(3):243–5. Available from: https://pubmed.ncbi.nlm.nih.gov/1561898/
Rodrigues CAO, Santos NHF, Barbosa SFA, Araújo DD de, Gusmão ROM, Vieira MA. Perfil de pacientes atendidos em um centro de atenção psicossocial. Revista de Enfermagem UFPE on line [Internet]. 2019 Sep 23 [cited 2022 Dec 1];13. Available from: https://periodicos.ufpe.br/revistas/revistaenfermagem/article/view/242177
Barbosa CG, Meira PRM, Nery JS, Gondim BB. Perfil epidemiológico dos usuários de um Centro de Atenção Psicossocial. SMAD, Rev Eletrônica Saúde Mental Álcool Drog [Internet]. 27 de fevereiro de 2020 [citado 1 de dezembro de 2022];16(1):1-8. Disponível em: https://www.revistas.usp.br/smad/article/view/167091
Freitas AA, de Souza RC. caracterização clínica e sociodemográfica dos usuários de um centro de atenção psicossocial (CAPES). Revista Baiana de Saúde Pública [Internet]. 2010 Jan 1 [cited 2022 Dec 1];34(3):530. Available from: https://rbsp.sesab.ba.gov.br/index.php/rbsp/article/view/53
Santos, Moraes C, Célia R, Jairo Calado Cavalcante, Mércia Zeviani Brêda, Bento J. O perfil epidemiológico dos usuários de um centro de atenção psicossocial. Revista de Enfermagem UFPE on line [Internet]. 2013 [cited 2022 Dec 1];7(3):679–87. Available from: https://periodicos.ufpe.br/revistas/revistaenfermagem/article/view/10280
Qiu H, He Y, Zhang Y, He M, Liu J, Chi R, et al. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Australian & New Zealand Journal of Psychiatry [Internet]. 2018 Oct 12 [cited 2022 Dec 1];52(12):1202–12. Available from: https://pubmed.ncbi.nlm.nih.gov/30309245/
Ortiz G, Hollen V, Schacht L. Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals. Journal of Psychiatric Practice [Internet]. 2016 Jul [cited 2022 Dec 1];22(4):283–97. Available from: https://pubmed.ncbi.nlm.nih.gov/27427840/
Kantorski LP, Treichel CA dos S, Santos CG dos, Menezes ES de, Almeida MD de, Alves PF, et al. Prevalence of psychotropic drug use and conformity of therapeutic dose among mental health users. Revista Brasileira de Enfermagem [Internet]. 2021 [cited 2022 Dec 1];74(6). Available from: https://pubmed.ncbi.nlm.nih.gov/34406232/
Roh D, Chang J-G, Kim C-H, Cho H-S, An SK, Jung Y-C. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Australian & New Zealand Journal of Psychiatry [Internet]. 2013 May 13 [cited 2022 Dec 1];48(1):52–60. Available from: https://pubmed.ncbi.nlm.nih.gov/23671214/
Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, et al. Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia. JAMA Psychiatry [Internet]. 2021 Nov 1 [cited 2022 Dec 1];78(11):1238. Available from: https://pubmed.ncbi.nlm.nih.gov/34406325/
De Sousa Soares D, Rolim Carvalho D, Trinta Ribeiro MD, Bessa Diniz EJ, Ferreira Rêgo Neto A. Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil. Trends in Psychiatry and Psychotherapy [Internet]. 2021 [cited 2022 Dec 1]; Available from: https://www.scielo.br/j/trends/a/XnPGdHbrBDbr48yCxCwf3Bh/
Cezaretto M, Silva EF de SF, Ambrizzi A, Biase VED de, Silva E de F, Cruz EMTN da, et al. Perfil clínico e sociodemográfico de pacientes com esquizofrenia refratária tratados em um centro terciário. Jornal Brasileiro de Psiquiatria [Internet]. 2014 Sep [cited 2022 Dec 1];63(3):185–90. Available from: https://www.scielo.br/j/jbpsiq/a/4DWgvb4XyJFvYRThzxL8gDH/?lang=pt
Stokes I, Griffiths SL, Jones R, Everard L, Jones PB, Fowler D, et al. Prevalence of treatment resistance and clozapine use in early intervention services. BJPsych Open [Internet]. 2020 Sep [cited 2022 Dec 1];6(5). Available from: https://pubmed.ncbi.nlm.nih.gov/32938513/
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Frederico Picanço Wambier, Tarcísio Fanha Dornelles, Fabiana Postiglioni Mansani, Julia Henneberg Hessman
This work is licensed under a Creative Commons Attribution 4.0 International License.
